There is a need to develop cell and molecular protection approaches for at-risk neurons in neurodegenerative diseases, and regenerative medicine offers designer cells to be used for factor-delivery in diseases like Parkinson's (PD) where we know that certain growth factors might, if delivered properly, have the ability to rescue a discrete population of nigrostriatal cells and hence slow or halt the progression of the disease. This proposal will use a novel cellular transplant approach to deliver glial cell line derived neurotrophic factor (GDNF) in comparable in vitro and in vivo bioassays of dopamine neuron degeneration.
Three specific aims focus on which astrocytes, from different sources, can be used to deliver GDNF to at risk dopamine neurons in a culture model of PD as well as a well-accepted rodent model (6-hydroxydopamine, 6- OHDA lesions of the neostriatum) of the disease.
Specific Aim 1 will establish the potential for autologous cellular repair by focusing on newly-generated """"""""immature"""""""" astrocytes derived from the mouse brain (e.g. adult cerebral cortex and striatum), and bone marrow versus mouse embryonic stem cells. These candidate astrocyte populations will be transduced with an eGFP-GDNF lentiviral construct to determine which population(s) is most amenable to stable growth factor transduction and release of the growth factor, for subsequent testing in an in vivo lesion-protection model (Aim 3).
Specific Aim 2 will look at adult human brain astrotypic and bone marrow-derived cells and their ability to be stably transduced with lenti-GDNF and release the growth factor as the mouse cells do in Aim 1.
Specific Aim 3 will assay the potential protective actions of GDNF-releasing mouse and human cells in DA depleted mice. These studies will incorporate methods already developed and tested in our laboratories, including cell culture, electrophysiology, gene therapy, cell grafting, immunophenotyping, biochemical and behavioral testing at PD models and repair, with the goal of developing a new therapeutic protocol for at-risk neuron protection and rescue in human PD. The possibility of using autologous cells derived from brain or bone marrow offers a tremendous therapeutic advantage for exploiting stem/progenitor as well as differentiated cells to slow and even halt the course of devastating neurological disorders. It is hypothesized that astrotypic cells, derived either from brain or bone marrow, have the ability to be engineered to release therapeutic factors in PD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS055165-05
Application #
8055564
Study Section
Clinical Neuroplasticity and Neurotransmitters Study Section (CNNT)
Program Officer
Sutherland, Margaret L
Project Start
2007-07-01
Project End
2014-03-31
Budget Start
2011-04-01
Budget End
2014-03-31
Support Year
5
Fiscal Year
2011
Total Cost
$309,996
Indirect Cost
Name
University of Florida
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Siebzehnr├╝bl, Florian A; Raber, Kerstin A; Urbach, Yvonne K et al. (2018) Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition. Proc Natl Acad Sci U S A 115:E8765-E8774
Reinartz, Roman; Wang, Shanshan; Kebir, Sied et al. (2017) Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma. Clin Cancer Res 23:562-574
Suslov, Oleg; Silver, Daniel J; Siebzehnrubl, Florian A et al. (2015) Application of an RNA amplification method for reliable single-cell transcriptome analysis. Biotechniques 59:137-48
Sarkisian, Matthew R; Siebzehnrubl, Dorit; Hoang-Minh, Lan et al. (2014) Detection of primary cilia in human glioblastoma. J Neurooncol 117:15-24
Candelario, Kate M; Steindler, Dennis A (2014) The role of extracellular vesicles in the progression of neurodegenerative disease and cancer. Trends Mol Med 20:368-74
Felsenstein, Kevin M; Candelario, Kate M; Steindler, Dennis A et al. (2014) Regenerative medicine in Alzheimer's disease. Transl Res 163:432-8
Siebzehnrubl, Florian A; Silver, Daniel J; Tugertimur, Bugra et al. (2013) The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med 5:1196-212
Silver, Daniel J; Siebzehnrubl, Florian A; Schildts, Michela J et al. (2013) Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment. J Neurosci 33:15603-17
Della Rocca, Domenico G; Willenberg, Bradley J; Ferreira, Leonardo F et al. (2012) A degradable, bioactive, gelatinized alginate hydrogel to improve stem cell/growth factor delivery and facilitate healing after myocardial infarction. Med Hypotheses 79:673-7
Sussman, Craig B; Rossignol, Candace; Zhang, Qizhi et al. (2012) Photoacoustic tomography can detect cerebral hemodynamic alterations in a neonatal rodent model of hypoxia-ischemia. Acta Neurobiol Exp (Wars) 72:253-63

Showing the most recent 10 out of 16 publications